We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
Publication, Part of Prescribing Costs in Hospitals and the Community
Hospital Prescribing - England, 2010
Official statistics- Publication Date:
- 18 Oct 2011
- Geographic Coverage:
- England
- Geographical Granularity:
- Regions, Country, Strategic Health Authorities
- Date Range:
- 01 Jan 2010 to 31 Dec 2010
Summary
This report compares expenditure between primary and secondary care in total and for selected areas, including medicines positively appraised by NICE. Specific areas covered this year are ADHD, psychosis and anti-TNF medicines.
Highlights
- Total prescribing costs in 2010 were £12.9 billion
- In 2010 hospital use accounted for 31.7 per cent of the total cost, up from 30.9 per cent in 2009.
- The cost of medicines rose by 4.8 per cent overall but by 7.7 per cent in hospitals
- Of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but adalimumab incurred the greatest cost in hospitals.
- The route by which patients receive drugs for Attention Deficit Hyperactivity Disorder varies widely between Strategic Health Authorities. In 2010 the proportion of drugs for ADHD (measured in Defined Daily Doses) prescribed in hospitals but dispensed in the community ranged from 10.4 per cent to 32.1 per cent.
Resources
Last edited: 30 March 2022 7:36 am